Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 1, 2010, Pages 71-84

  Zenz, Thorsten ^a   Fröhling, Stefan ^a   Mertens, Daniel ^a,b   Döhner, Hartmut ^a   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Cooperation Unit Mechanisms of Leukemogenesis ^*  (Germany)

Author keywords

11q deletion; 17p deletion; CLL; genomic aberrations; IGHV; p53; predictive factors; prognosis; trisomy 12

Indexed keywords

ADAM PROTEIN; ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ATM PROTEIN; B LYMPHOCYTE RECEPTOR; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CD38 ANTIGEN; CELL MARKER; FLAVOPIRIDOL; FLUDARABINE; GYRASE INHIBITOR; LACTATE DEHYDROGENASE; LENALIDOMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHOTRANSFERASE INHIBITOR; PLATINUM DERIVATIVE; PROTEIN KINASE SYK INHIBITOR; PROTEIN KINASE ZAP 70; PROTEIN P53; THYMIDINE KINASE; TUMOR MARKER;

BLOOD CHEMISTRY; CANCER CHEMOTHERAPY; CANCER STAGING; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE MARKER; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC PARAMETERS; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN VARIABLE REGION; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHADENOPATHY; LYMPHOCYTE COUNT; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTE COUNT; TREATMENT RESPONSE;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ANTIGEN, B-CELL; RISK FACTORS;

EID: 77956632843     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.12.003     Document Type: Review

References (96)

1. N. Chiorazzi, K.R. Rai, and M. Ferrarini Chronic lymphocytic leukemia N Engl J Med 352 2005 804 815
2. T. Zenz, H. Dohner, and S. Stilgenbauer Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia Best Pract Res Clin Haematol 20 2007 439 453
3. T. Zenz, D. Mertens, and R. Küppers From pathogenesis to treatment of chronic lymphocytic leukaemia Nature Reviews Cancer 51 2010 37 50
4. W.G. Wierda, S. O'Brien, and X. Wang Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment J Clin Oncol 27 2009 1637 1643
5. D.G. Oscier, A.C. Gardiner, and S.J. Mould Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors Blood 100 2002 1177 1184
6. C. Moreno, and E. Montserrat New prognostic markers in chronic lymphocytic leukemia Blood Rev 22 2008 211 219
7. M. Hallek, I. Langenmayer, and C. Nerl Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia Blood 93 1999 1732 1737
8. H. Dohner, S. Stilgenbauer, and A. Benner Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 2000 1910 1916 (Pubitemid 32064784)
9. A. Krober, T. Seiler, and A. Benner V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia Blood 100 2002 1410 1416
10. D.J. Sargent, B.A. Conley, and C. Allegra Clinical trial designs for predictive marker validation in cancer treatment trials J Clin Oncol 23 2005 2020 2027
11. S.J. Mandrekar, and D.J. Sargent Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges J Clin Oncol 27 2009 4027 4034
12. K.R. Rai, A. Sawitsky, and E.P. Cronkite Clinical staging of chronic lymphocytic leukemia Blood 46 1975 219 234
13. J.L. Binet, A. Auquier, and G. Dighiero A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer 48 1981 198 206
14. T. Seiler, H. Dohner, and S. Stilgenbauer Risk stratification in chronic lymphocytic leukemia Semin Oncol 33 2006 186 194
15. E. Montserrat, J. Sanchez-Bisono, and N. Vinolas Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance Br J Haematol 62 1986 567 575
16. C. Rozman, E. Montserrat, and J.M. Rodriguez-Fernandez Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases Blood 64 1984 642 648
17. M.A. Bergmann, B.F. Eichhorst, and R. Busch Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG) ASH Annual Meeting Abstracts 110 2007 2038
18. H.M. Kantarjian, T. Smith, and E. Estey Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia Am J Med 93 1992 599 604
19. S. Stilgenbauer, T. Zenz, and D. Winkler Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group J Clin Oncol 27 2009 3994 4001
20. U. Klein, and R. Dalla-Favera Germinal centres: role in B-cell physiology and malignancy Nat Rev Immunol 8 2008 22 33
21. R.N. Damle, T. Wasil, and F. Fais Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia Blood 94 1999 1840 1847
22. T.J. Hamblin, Z. Davis, and A. Gardiner Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia Blood 94 1999 1848 1854
23. F. Fais, F. Ghiotto, and S. Hashimoto Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors J Clin Invest 102 1998 1515 1525
24. D. Catovsky, S. Richards, and E. Matutes Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Lancet 370 2007 230 239
25. M.R. Grever, D.M. Lucas, and A.J. Johnson Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia Best Pract Res Clin Haematol 20 2007 545 556
26. S. Stilgenbauer, T. Zenz, and D. Winkler Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial ASH Annual Meeting Abstracts 112 2008 781
27. S. Stilgenbauer, B.F. Eichhorst, and R. Busch Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG ASH Annual Meeting Abstracts 112 2008 2089
28. T.J. Kipps The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia Best Pract Res Clin Haematol 20 2007 415 424
29. U. Klein, Y. Tu, and G.A. Stolovitzky Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells J Exp Med 194 2001 1625 1638
30. A. Rosenwald, A.A. Alizadeh, and G. Widhopf Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia J Exp Med 194 2001 1639 1647
31. A. Wiestner, A. Rosenwald, and T.S. Barry ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile Blood 101 2003 4944 4951
32. G. Roos, A. Krober, and P. Grabowski Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia Blood 111 2008 2246 2252
33. B.T. Messmer, D. Messmer, and S.L. Allen In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells J Clin Invest 115 2005 755 764
34. R.N. Damle, S. Temburni, and C. Calissano CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells Blood 110 2007 3352 3359
35. P. Ghia, K. Stamatopoulos, and C. Belessi Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene Blood 105 2005 1678 1685
36. F. Murray, N. Darzentas, and A. Hadzidimitriou Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis Blood 111 2008 1524 1533
37. K. Stamatopoulos, C. Belessi, and C. Moreno Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations Blood 109 2007 259 270
38. G. Tobin, U. Thunberg, and K. Karlsson Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia Blood 104 2004 2879 2885
39. M.R. Grever, D.M. Lucas, and G.W. Dewald Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 J Clin Oncol 25 2007 799 804
40. S. Hewamana, T.T. Lin, and C. Jenkins The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine Clin Cancer Res 14 2008 8102 8111
41. M. Crespo, F. Bosch, and N. Villamor ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia N Engl J Med 348 2003 1764 1775 (Pubitemid 36514707)
42. J.A. Orchard, R.E. Ibbotson, and Z. Davis ZAP-70 expression and prognosis in chronic lymphocytic leukaemia Lancet 363 2004 105 111
43. L.Z. Rassenti, L. Huynh, and T.L. Toy ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia N Engl J Med 351 2004 893 901
44. A. Krober, J. Bloehdorn, and S. Hafner Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia J Clin Oncol 24 2006 969 975
45. L.Z. Rassenti, S. Jain, and M.J. Keating Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia Blood 112 2008 1923 1930
46. M. Corcoran, A. Parker, and J. Orchard ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia Haematologica 90 2005 1078 1088
47. M. Esteller Epigenetics in cancer N Engl J Med 358 2008 1148 1159
48. A. Raval, D.M. Lucas, and J.J. Matkovic TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia J Clin Oncol 23 2005 3877 3885
49. F.J. Li, S. Ding, and J. Pan FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia Blood 112 2008 179 187
50. M.B. van't Veer, A.M. Brooijmans, and A.W. Langerak The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia Haematologica 91 2006 56 63
51. D. Kienle, A. Benner, and C. Laufle Gene expression markers for genetic risk groups and survival in cronic lymphocytic leukemia Haematologica 95 2010 102 109
52. M. Hallek, B.D. Cheson, and D. Catovsky Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 2008 5446 5456
53. G.A. Calin, C.D. Dumitru, and M. Shimizu Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proc Natl Acad Sci U S A 99 2002 15524 15529
54. A. Cimmino, G.A. Calin, and M. Fabbri miR-15 and miR-16 induce apoptosis by targeting BCL2 Proc Natl Acad Sci U S A 102 2005 13944 13949
55. M. Lagos-Quintana, R. Rauhut, and W. Lendeckel Identification of novel genes coding for small expressed RNAs Science 294 2001 853 858
56. H. Dohner, S. Stilgenbauer, and M.R. James 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis Blood 89 1997 2516 2522
57. B. Austen, J.E. Powell, and A. Alvi Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL Blood 106 2005 3175 3182
58. B. Austen, A. Skowronska, and C. Baker Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion J Clin Oncol 25 2007 5448 5457
59. A.L. Bredemeyer, G.G. Sharma, and C.Y. Huang stabilizes DNA double-strand-break complexes during V(D)J recombination Nature 442 2006 466 470
60. K. Kojima, M. Konopleva, and T. McQueen Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia Blood 108 2006 993 1000
61. O.G. Best, A.C. Gardiner, and A. Majid A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL Leukemia 2008
62. A.R. Pettitt, P.D. Sherrington, and G. Stewart p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation Blood 98 2001 814 822
63. T. Stankovic, P. Weber, and G. Stewart Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia Lancet 353 1999 26 29
64. A.M. Tsimberidou, C. Tam, and L.V. Abruzzo Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia Cancer 115 2009 373 380
65. T. Zenz, J. Smadova, and D. Vollmer TP53 Abnormalities in Chronic Lymphocytic Leukemia Exhibit a Disease Specific Profile: Meta-Analysis of 270 Mutations ASH Annual Meeting Abstracts 112 2008 2077
66. H. Dohner, K. Fischer, and M. Bentz p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Blood 85 1995 1580 1589
67. F. Dicker, H. Herholz, and S. Schnittger The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype Leukemia 23 2009 117 124
68. D. Rossi, M. Cerri, and C. Deambrogi The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness Clin Cancer Res 15 2009 995 1004
69. T. Zenz, A. Krober, and K. Scherer Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up Blood 112 2008 3322 3329
70. P. Hillmen, A.B. Skotnicki, and T. Robak Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia J Clin Oncol 25 2007 5616 5623
71. J.C. Byrd, T.S. Lin, and J.T. Dalton Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia Blood 109 2007 399 404
72. A. Chanan-Khan, K.C. Miller, and L. Musial Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study J Clin Oncol 24 2006 5343 5349
73. P. Dreger, P. Corradini, and E. Kimby Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus Leukemia 21 2007 12 17
74. A.R. Pettitt, E. Matutes, and D. Oscier Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects Leukemia 20 2006 1441 1445
75. J. Schetelig, A. van Biezen, and R. Brand Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis J Clin Oncol 26 2008 5094 5100
76. S. el Rouby, A. Thomas, and D. Costin p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression Blood 82 1993 3452 3459
77. M. Trbusek, J. Malcikova, and J. Smardova Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment Leukemia 20 2006 1159 1161
78. S. Frohling, C. Scholl, and D.G. Gilliland Genetics of myeloid malignancies: pathogenetic and clinical implications J Clin Oncol 23 2005 6285 6295
79. L. Kujawski, P. Ouillette, and H. Erba Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia Blood 112 2008 1993 2003
80. H. Nahi, S. Lehmann, and L. Mollgard Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion Br J Haematol 127 2004 285 291
81. C. Mayr, M.R. Speicher, and D.M. Kofler Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia Blood 107 2006 742 751
82. C. Haferlach, F. Dicker, and S. Schnittger Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping Leukemia 21 2007 2442 2451
83. M. Buchner, S. Fuchs, and G. Prinz Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia Cancer Res 69 2009 5424 5432
84. A. Veldurthy, M. Patz, and S. Hagist The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes Blood 112 2008 1443 1452
85. T. Zenz, D. Mertens, and H. Dohner Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications Leuk Lymphoma 49 2008 864 873
86. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
87. N. Schultz, E. Lopez, and N. Saleh-Gohari Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination Nucleic Acids Res 31 2003 4959 4964
88. H. Farmer, N. McCabe, and C.J. Lord Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
89. H.E. Bryant, N. Schultz, and H.D. Thomas Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
90. H. Jiang, H.C. Reinhardt, and J. Bartkova The combined status of ATM and p53 link tumor development with therapeutic response Genes Dev 23 2009 1895 1909
91. T. Zenz, J. Mohr, and J. Edelmann Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway Leuk Lymphoma 50 2009 510 513
92. C. Scholl, S. Frohling, and I.F. Dunn Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells Cell 137 2009 821 834
93. J. Downward Finding the weakness in cancer N Engl J Med 361 2009 922 924
94. C.L. Sawyers Finding and drugging the vulnerabilities of RAS-dependent cancers Cell 137 2009 796 798
95. V.N. Ngo, R.E. Davis, and L. Lamy A loss-of-function RNA interference screen for molecular targets in cancer Nature 441 2006 106 110
96. A.C. Rawstron, F.L. Bennett, and S.J. O'Connor Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia N Engl J Med 359 2008 575 583